The human counterpart hdm2 of the murine doubleminute 2 (mdm2) gene encodes a 90-kD protein (HDM2) that inhibits the function of the p53 tumor suppressor. Hdm2 is ampli®ed in approximately 30% of sarcomas, leading to overproduction of HDM2 and inactivation of p53. Using immunohistochemistry to screen a panel of human tumors for HDM2 overproduction, we detected high levels of HDM2 in the cytoplasm in 25% of lung tumors as opposed to its normal localization in the nucleus. These samples contained full-length hdm2 and several alternate-splice forms of hdm2 mRNA. Sequence analysis revealed deletions in the alternate-splice forms of the p53 binding domain and absence of a nuclear localization signal. In transient transfection assays, one of the alternate-splice forms, HDM2 ALT1 , bound and sequestered full-length HDM2 in the cytoplasm. In addition, the binding of HDM2 ALT1 to HDM2 inhibited the interaction of HDM2 with p53, thus enhancing p53 transcriptional activity. These data suggest the existence of another level of regulation of HDM2 which increases the activity of p53. Oncogene (2001) 20, 4041 ± 4049.
Introduction
The murine double-minute 2 (mdm2) gene was originally cloned as an ampli®ed gene present on double minute chromosomes in a tumorigenic 3T3DM murine cell line (Fakharzadeh et al., 1991) . MDM2 binds the amino terminal transactivation domain of the p53 tumor suppressor and inhibits its function as a transcriptional activator of genes involved in growth arrest or apoptosis (Momand et al., 1992; Chen et al., 1993 Oliner et al., 1993) . Mechanistically, the interaction of MDM2 with p53 induces the rapid degradation of p53 by ubiquitin-mediated proteolysis (Haupt et al., 1997; Kubbutat et al., 1997 Kubbutat et al., , 1998 . The importance of this interaction in vivo became clear from analysis of mdm2 null embryos, whose early lethality was completely rescued if p53 was also deleted (Jones et al., 1995; Montes de Oca Luna et al., 1995) . Interestingly, the p53 protein also induces the transcription of the mdm2 gene and thus regulates its own levels in a negative feedback loop (Juven et al., 1993; Wu et al., 1993; Barak et al., 1994) .
MDM2 is also able to transform cells, perhaps because of its ability to inhibit p53. Overexpression of the mdm2 gene in NIH3T3 cells produces a transformed phenotype (Fakharzadeh et al., 1991) . In addition, the mdm2 gene can immortalize rat embryo ®broblasts and cooperate with activated ras to transform these ®broblasts (Finlay, 1993) . In vivo, the overexpression of mdm2 in murine mammary epithelium leads to breast tumors with long latency (Lundgren et al., 1997) . These data suggest that mdm2 is an oncogene. However, other studies have suggested that HDM2 disrupts the cell cycle and is inhibitory to cell survival. For example, the overexpression of hdm2, the human homolog of mdm2, in normal ®broblasts and several untransformed cell lines results in arrest of the cell cycle between G1 and S phases (Brown et al., 1998) . In vivo, overexpression of mdm2 in mouse breast epithelial cells disrupts the cell cycle by allowing multiple rounds of DNA replication without cytokinesis (Lundgren et al., 1997) . This defect is independent of p53, suggesting that other cellular changes must compensate for tolerance of HDM2 overexpression in human tumors.
This discrepancy may be explained in part by the dierent sized MDM2 proteins detectable in cells overexpressing mdm2 or hdm2 . It has been hypothesized that these dierent proteins arise through proteolytic cleavage, post-translational modi®cation, or alternative splicing. In fact, multiple hdm2 transcripts lacking a p53 binding domain have been detected in some human tumors (Sigalas et al., 1996; Matsumoto et al., 1998) . Although the biochemical functions of these protein products have not yet been determined, their existence suggests that MDM2 may perform additional unknown functions.
Hdm2 has been mapped to chromosome 12q13-14 and is ampli®ed in over 30% of sarcomas, but ampli®cation is rare in other tumor types (Oliner et al., 1992; Momand et al., 1998) . However, recent data suggest that overproduction of HDM2 may result from mechanisms other than gene ampli®cation and include chromosomal translocations (Berberich and Cole, 1994) , increased levels of hdm2 mRNA (Bueso-Ramos et al., 1993; Watanabe et al., 1994) , or enhanced translation (Landers et al., 1994; Capoulade et al., 1998) .
To examine the regulation of HDM2 production in a broad range of tumor types, we screened a panel of human tumors to ®rst determine if increased levels of HDM2 protein are independent of gene ampli®cation. In our studies, HDM2 was overproduced in non-small cell lung carcinomas independently of ampli®cation. To our surprise, in 25% of these tumors HDM2 was also aberrantly localized to the cytoplasm. This intriguing result led us to explore the functional signi®cance of this localization. We discovered that the cytoplasmic compartmentalization of HDM2 was due to binding and sequestration by an alternative-spliced HDM2 product (HDM2   ALT1 ). In addition, the binding of HDM2 ALT1 to full-length HDM2 prevented HDM2 from binding p53 and inhibiting p53 function. Since HDM2 binds and degrades p53, the disruption of the HDM2/p53 interaction by HDM2 ALT1 would lead to increased p53 activity.
Results

HDM2 is aberrantly localized to the cytoplasm in tumors
The hdm2 gene is ampli®ed in 30% of sarcomas, leading to the overproduction of HDM2 and inhibition of p53 function (Oliner et al., 1992; Cordon-Cardo et al., 1994; Momand et al., 1998) . However, other mechanisms of HDM2 overproduction have recently been observed in some tumor types and in cells in culture, suggesting that several mechanisms regulate HDM2 production (Berberich and Cole, 1994; BuesoRamos et al., 1993; Landers et al., 1994; Watanabe et al., 1994) . To determine if mechanisms other than ampli®cation regulate HDM2 protein levels in tumors in which ampli®cation is rare (Momand et al., 1998) , we systematically surveyed 117 human tumors for overproduction of HDM2 using a monoclonal antibody against HDM2 (Table 1) . High HDM2 protein levels were seen in 15% of tumors and were most evident in lung (45%) and thyroid (43%) tumors. Additionally, 23% of kidney tumors and 8% of salivary gland tumors also contained high levels of HDM2. In contrast, none of 21 ovarian tumors had high levels of HDM2. The sample number was too small to reach any conclusions for the remaining tumor types analysed.
We undertook a more detailed analysis of HDM2 in non-small cell lung carcinoma because hdm2 ampli®cation is rare yet the overproduction of HDM2 was detected by immunohistochemistry suggesting alternate mechanisms of HDM2 overexpression (Momand et al., 1998) . Because of the functional relation between HDM2 and p53, we also scored mutations in p53 (Figure 1 ). Since wild-type p53 is under most circumstances not detected by immunohistochemistry because of its short half-life, positive immunoreactivity for p53 would indicate either a mutation in p53 or stabilization of wild-type p53. Of a total of 33 adenocarcinomas and squamous cell carcinomas examined, 55% were positive for HDM2 overproduction (Figure 1c, e, g, i) . Of these, 55% were also positive for p53 immunoreactivity (Figure 1f,j) . Single-strand conformational polymorphism (SSCP) analysis and sequencing of exons 5 ± 10, the most commonly mutated region of p53, revealed speci®c mutations in p53 in 80% of cases analysed (data not shown). Thus, some of these lung tumors contained both high levels of HDM2 and mutations in p53.
In addition, these experiments led to an unexpected result: in 25% of these lung tumors, HDM2 was localized to the cytoplasm as opposed to its usual nuclear localization (Chen et al., 1995) . Examples of the immunohistochemistry are shown in Figure 1 . Sample 29 shows HDM2 localized almost exclusively in the cytoplasm whereas in samples 50 and 57, it is localized to the cytoplasm as well as the nucleus. Overproduced HDM2 is localized to the nucleus in sample 21 and is not detectable in sample 25. The cytoplasmic localization of HDM2 was independent of p53 status. Two of the samples with cytoplasmic HDM2 contain speci®c p53 mutations (data not shown). Subcellular localization also did not correlate with tumor grade or stage, nor with the levels of HDM2 and p53 (data not shown). The observation that HDM2 was localized to the cytoplasm suggests that it is not likely to inhibit nuclear p53 function.
To determine if overproduction of HDM2 in nonsmall cell lung tumors with or without cytoplasmic localization of HDM2 was due to its ampli®cation, we performed Southern blot analysis of normal and tumor DNA samples from several individuals. We found that HDM2 overexpression was independent of ampli®cation in these non-small cell lung carcinomas regardless of localization of HDM2 (data not shown).
Alternatively spliced HDM2 transcripts are produced in tumors with cytoplasmic HDM2
To determine whether a mutation in or deletion of the HDM2 putative nuclear localization signal resulted in the cytoplasmic localization of HDM2, we performed SSCP analysis of hdm2 RT ± PCR products. We did not ®nd any variants in full-length hdm2, which suggested that HDM2 was wild-type in these tumors (data not shown). We did, however, detect three smaller RT ± PCR products limited solely to tumors with cytoplasmic HDM2 (Figure 2a ). RT ± PCR analysis of p53 generated only full-length products indicating that there is no general defect in RNA integrity or isolation in these tumor samples ( Figure  2a ). Sequence analysis of the HDM2 RT ± PCR fragments from several tumor samples revealed that they encoded smaller HDM2 products ( Figure 2b ). HDM2 ALT1 encodes amino acids 1 ± 27 and 300 ± 491. HDM2 ALT2 encodes amino acids 1 ± 27 and 222 ± 491 and HDM2
ALT3 encodes amino acids 1 ± 52 and 222 ± 491. These smaller HDM2 proteins had previously been found in bladder and ovarian cancers and in astrocytomas (Matsumoto et al., 1998; Sigalas et al., 1996) , although their localization has not previously been examined. A comparison of these sequences to the genomic structure showed that HDM2 ALT1 , HDM2
ALT2
and HDM2
ALT3
are derived from alternate-spliced forms of hdm2. All three alternate-splice forms lacked most of the p53 binding domain and the nuclear localization signal. The acidic domain is also absent from HDM2
ALT1
. All forms retained the zinc and RING ®ngers, however. These alternate-spliced forms of HDM2 also lacked the antibody epitope used in immunohistochemistry (Figure 2b) . Thus, only the fulllength HDM2 in the cytoplasm was detected by immunohistochemistry ( Figure 1 ).
HDM2
ALT1 binds and sequesters HDM2 in the cytoplasm
One possible explanation for the aberrant localization of full-length HDM2 was that the alternate forms bind and sequester full-length HDM2 in the cytoplasm. To examine interaction in vivo, we ®rst screened tumor cell lines for the presence of endogenous HDM2 proteins postulating that as in the tumor samples (Figures 1 and  2 ) some might express HDM2 alternate-spliced products. Several HDM2 products, possibly from protein cleavage or alternative-splicing, were recognized by an a-HDM2 polyclonal antibody in MCF7, H1299, and RKO cells. However, HDM2 ALT1 , migrating the same distance as an in vitro translated protein (data not shown), was detected by Western blot analysis with a-HDM2 polyclonal antibody only in MCF7 cells (Figure 3a) . Since MCF7 cells and all tumor samples with cytoplasmic localization of HDM2 contained HDM2 ALT1 (Figure 2a) , we chose to focus on this product. Second, we screened several HDM2 antibodies for speci®city to either form of HDM2. In vitro transcribed and translated HDM2 and HDM2
ALT1
proteins were immunoprecipitated with a series of Figure 1 Immunohistochemistry of tumor samples with HDM2 and p53 antibodies. Paran-embedded tissue sections of adenocarcinomas of the lung (samples numbered 25, 21, 50) and squamous cell lung carcinomas (samples numbered 57, 29) stained for HDM2 with antibody SMP14 (a,c,e,g,i) or for p53 with antibody d, f, h, j) . Both cytoplasmic and nuclear localization of HDM2 is observed in e and g and almost exclusively in the cytoplasm in i, whereas p53 staining in these tumors is negative (d,h) or in the nucleus (b,f,j). Photographs taken at 2006and 4006magni®cation antibodies (Figure 3b ). Ab-1 and H221 antibodies were speci®c for full-length HDM2, whereas the N-terminal antibody N20 recognizes both forms of HDM2 ( Figure  3b ). Since we predicted HDM2 ALT1 to be localized in the cytoplasm, we isolated MCF7 cytoplasmic fractions to increase our chances of observing an interaction.
Immunoprecipitation experiments with Ab-1 and H221 antibodies that recognize only full-length HDM2 followed by Western blot analysis with N20 antibody showed the interaction between full-length HDM2 and HDM2 ALT1 ( Figure 3c ). In addition, HDM2
ALT1 was more abundant in the cytoplasmic fraction as opposed to the nuclear fraction. The cytoplasmic localization of HDM2 was also evident in MCF7 cells by immunostaining with the SMP14 antibody (Figure 3d) . In RKO and H1299 cells, which do not have detectable HDM2
ALT1 , full-length HDM2 was localized to the nucleus (Figure 3d ). P53 was detected in the nucleus in MCF7 cells (Figure 3d) . Interestingly, p53 is excluded from the nucleus in RKO cells (Figure 3d ). H1299 cells are null for p53.
We hypothesized that HDM2 ALT1 sequesters fulllength HDM2 in the cytoplasm since in MCF7 cells endogenous HDM2
ALT1 was shown to interact with HDM2 in the cytoplasm and lacks a nuclear localization signal. To test this hypothesis, we transfected p53/ mdm2 double null mouse embryo ®broblasts (McMasters et al., 1996) with expression plasmids encoding HDM2, HDM2 ALT1 , or both. After 48 h, the cells were stained with SMP14, the antibody that recognizes only full-length HDM2, or an a-HDM2 polyclonal antibody that recognizes both (Figure 4a ). Cells transfected with only HDM2 had positive staining using SMP14 ( Figure  4b , panels A and B) or a-HDM2 (data not shown) predominantly in the nucleus. Reciprocally, immunoreactivity towards the a-HDM2 polyclonal antibody in cells transfected with HDM2 ALT1 occurred solely in the cytoplasm (Figure 4b , panels C and D). In contrast to cells transfected with HDM2 alone, immunoreactivity of full-length HDM2 to SMP14, which does not recognize HDM2
, was apparent in the cytoplasm when both HDM2 and HDM2 ALT1 were transfected ) from RT ± PCR were directly sequenced and the predicted proteins are shown ( Figure 4b , panels E, F and G). The p53/mdm2 double null cells did not stain with the SMP14 antibody ( Figure 4b , panel H) nor with the a-HDM2 antibody (data not shown), indicating that the antibodies were speci®c to HDM2.
HDM2
ALT1 prevents HDM2 from binding to p53 and inhibiting p53 activity
The alternate-spliced form of HDM2, HDM2 ALT1 , which lacks the p53 binding domain, binds and causes the aberrant subcellular localization of HDM2. Since HDM2 binds and inhibits p53 transcriptional activity, we wanted to test the eects of HDM2 ALT1 on p53 function. Speci®cally we wished to ask whether HDM2 ALT1 increased p53 function by inhibiting its negative regulator, HDM2. First, we performed in vitro coupled transcription-translation experiments where we attempted to pull-down radiolabeled trimeric protein complexes composed of HDM2, p53, and His-HDM2 ALT1 . We found that the antibody PAb421 against p53 immunoprecipitated HDM2 bound to p53 (Figure 5a) . Likewise, the a-his antibody immunoprecipitated HDM2 bound to His-HDM2 ALT1 (Figure 5a) . However, His-HDM2 ALT1 could not bind HDM2 if added to the reaction after HDM2 was bound to p53. If p53 was added last to the reaction, it did not interfere with the interaction between the HDM2 proteins although a very slight amount of p53 was detected as a trimeric complex (Figure 5a ). These data indicate that HDM2 can bind either p53 or HDM2 ALT1 but not both simultaneously. Since we were unable to detect HDM2 binding to p53 in vitro in the presence of HDM2 ALT1 , we tested the eect of this alternative-spliced form on p53 activity in vivo. U2OS cells, which are wild-type for p53 and transfect well, were transfected with HDM2 or HDM2 ALT1 expression plasmid, in addition to a p21 or mdm2 p53 responsive luciferase reporter construct (Figure 5b,c) . Transfections were normalized by b-gal activities. The transfectants were assayed for p53 transcriptional activity (Figure 5b ). p53 transfectants were designated as having 100% p53 activity. Transfection of hdm2 decreased p53 activity 73 ± 89% as previously reported by other groups (Haupt et al., 1997; Kubbutat et al., 1997 Kubbutat et al., , 1998 . In contrast, transfection of HDM2 ALT1 increased p53 activity 69 ± 79% presumably due to its binding to endogenous HDM2 (Figure 5b) . Staining of the HDM2 ALT1 transfectants shows full-length HDM2 excluded from the nucleus as opposed to the nuclear localization in mock-transfected cells (Figure 5c ). Thus, in transient transfection experiments, the addition of HDM2 ALT1 increased p53 transcriptional activity by inhibition of HDM2 function through physical separation of HDM2 in the cytoplasm.
Discussion
Our observations that HDM2 was localized in the cytoplasm in non-small cell lung carcinomas suggested that it would not be able to inhibit p53 function in the nucleus. In pursuing the reasons for the aberrant localization, we discovered that full-length HDM2 was sequestered in the cytoplasm by binding a shorter HDM2 protein, HDM2
ALT1
. HDM2 appears to bind either HDM2 ALT1 or p53, but not both. Thus, one role of HDM2 ALT1 appears to be to negatively regulate HDM2 preventing it from inhibiting p53 activity.
Numerous experiments described in this manuscript show the interaction of HDM2 with HDM2
. In vivo using MCF7 cells, which express HDM2 ALT1 , the interaction was very clear. Moreover, the interaction was most visible in the cytoplasm, the predicted localization of the HDM2/HDM2 ALT1 complex. Immuno¯uorescent staining of full length HDM2 in MCF7 cells indicated localization to the cytoplasm and transfection experiments in cells lacking p53 indicated the ability of HDM2 ALT1 to pull endogenous HDM2 into the cytoplasm. Importantly, we could not detect HDM2 homodimerization (data not shown) suggesting that other sequences within HDM2 prevent homodimerization.
Interestingly, in vitro experiments suggest the interaction does not aect p53 already bound to HDM2 suggesting that other mechanisms must also be involved in the activation of p53. Two known mechanisms disrupt the interaction of HDM2 with p53 and thus lead to increased p53 activity. In one, serine 15, serine 20, and threonine 18 are phosphorylated, disrupting MDM2 binding (Shieh et al., 1997; Unger et al., 1999; Sakaguchi et al., 2000) . Thus, upon phosphorylation of p53 serine 15, the freed HDM2 ALT1 , whereas a-HDM2 recognizes both. (b) Mouse embryo ®broblasts null for both p53 and mdm2 were transfected with CMV-HDM2 (a and b), CMV-HDM2 ALT1 (c and d), or both (e,f, and g). Control cells were transfected with an empty vector (h). Cells were stained 48 h after transfection with SMP14 (a,b,e,f,g, and h) or a-HDM2 (c and d). Texas-red conjugated secondary antibodies were used for detection. Cells are photographed at 4006magni®cation could interact with HDM2 ALT1 and be sequestered in the cytoplasm. In the second mechanism, p14 ARF , the product of the p16INK4a locus, binds to HDM2, preventing its binding and degradation of p53 (Quelle et al., 1995; Pomerantz et al., 1998; Zhang et al., 1998; Kamijo et al., 1998) . When p14 ARF function in human tumors is altered by mutation, both HDM2 levels and degradation of p53 increase (Kamijo et al., 1997; Stott et al., 1998) . We have not examined the role of HDM2 ALT1 in regulating the p14 ARF /HDM2 interaction, but MCF7 cells which express HDM2 ALT1 are devoid of p14 ARF (Stott et al., 1998) . As expected, the interaction of HDM2 with HDM2 ALT1 results in p53 transactivation. Transient transfections show a signi®cant increase in p53 activity upon expression of HDM2
. Thus, it appears that multiple interactions ensure that p53 is functional. Initial interactions involve dislodging HDM2 bound to p53 with subsequent interactions sequestering HDM2, which is activated by p53, in the cytoplasm. These data con®rm that removal of HDM2 from the nucleus results in p53 transcriptional activation and further supports the hypothesis that multiple pathways regulate p53.
We still do not understand why non-small cell lung carcinomas and tumor cell lines such as MCF7 express HDM2 ALT1 . The end result would be higher p53 levels and growth arrest or apoptosis. Since these cells are obviously cycling, other mechanisms must inactivate the p53 pathway. In fact, some of the non-small cell lung tumors that had high HDM2 levels in the cytoplasm also had mutations in p53 (data not shown). Perhaps in response to abnormal growth signals, cells express HDM2 ALT1 to activate p53, but subsequent p53 mutations in p53 or in the pathway derail p53 function. The most exciting future goal will be to determine what signals initiate expression of HDM2 ALT1 .
Materials and methods
Normal and tumor tissues
Paran-embedded tumor samples were obtained from the Department of Pathology at The University of Texas MD Anderson Cancer Center. Samples were ®xed in 10% buered formalin, embedded in paran, and sectioned. When available, fresh-frozen tumor and normal tissue samples from donors were collected.
Immunohistochemistry
Paran-embedded tissue sections were stained for immunoreactivity to HDM2 (SMP-14, Santa Cruz Biotechnology, Inc.) or p53 (Bp53-12, Santa Cruz Biotechnology, Inc.) using the Vectastain ABC Elite Kit (Vector Laboratories). Brie¯y, sections were deparanized in a xylene-to-ethanol gradient. The slides were steamed for 25 min in citrate buer (pH 6.0) and then rinsed in H 2 O. Endogenous peroxidase activity was blocked by incubating sections in 3% hydrogen peroxide for 15 min. The slides were blocked in horse serum for 30 min and then incubated in primary antibody diluted in 2% horse serum (HDM2, 1 : 200; p53, 1 : 1000) for 1 h at 378C. Secondary antibody and ABC reagent were added as described in the Vectastain protocol. Diaminobenzidine substrate (Vector Laboratories) was used according to the manufacturer's instructions. The sections were counterstained in Nuclear Fast Red, dehydrated through an ethanol-toxylene gradient, and mounted under glass coverslips in Permount (Sigma). Photographs were taken with a Zeiss microscope with a 20 or 406lens.
Southern blot analysis
A 5-mg sample of genomic DNA was digested with EcoRI overnight, electrophoretically separated on a 0.8% agarose gel, and blotted to nylon membrane (Oncor) in 0.4 N NaOH. The membranes were prehybridized at 658C for 1 h in hybridization buer containing 1% SDS, 10% dextran sulfate, 1 M NaCl, and 100 mg/ml salmon sperm DNA. The blot was then hybridized overnight at 658C with 1610 6 c.p.m./ml of the hdm2 cDNA random-labeled with 32 P-dCTP. Membranes were washed and subjected to autoradiography at 7808C for 1 ± 3 days.
Mutational analysis
Genomic DNA was extracted from normal and tumor tissue using a modi®cation of a protein salting-out procedure (Miller et al., 1988) . PCR ampli®cation, single-strand conformational polymorphism (SSCP) analysis, and sequencing for p53 was performed as described in Evans et al. (1998) . The hdm2 nuclear localization signal was screened for mutations using SSCP as described above with primers 5'-TGAATTATCTGGTGAACGAC-3' and 5'-GTCCCTGTA-GATTCACTGCT-3'.
Nested RT ± PCR mRNA was isolated from normal tissue, tumor tissue, or tissue-culture cells using Dynabeads (Dynal). Approximately 1 mg of mRNA was used for RT ± PCR using the First Strand cDNA Synthesis kit (Stratagene) with random hexamers. PCR reactions occurred in a total volume of 15 ml containing 1 ml of RT ± PCR reaction mixture with 10 pmol of each primer, 0.25 mM dATP, dGTP, dCTP, and dTTP and 0.15 U Taq DNA polymerase (Boeringer ± Mannheim), and the buer provided by Boeringer ± Mannheim. The primers for hdm2 were as described in Sigalas et al. (1996) . The primers for p53 were 5'-ATTTGATGCTGTCCCCGGACGATATT-GAAC-3' and 5'-ACCCTTTTTGGACTTCAGGTGGCTG-GAGTG-3'. The PCR thermocycler parameters consisted of an initial cycle of 948C for 5 min followed by 35 cycles of 948C for 1 min, 558C for 1 min and 728C for 2 min, and a ®nal extension for 7 min at 728C. Bands were excised from the agarose gel, cloned and sequenced.
In vitro binding assays T7 expression vectors containing p53, hdm2, or hdm2 ALT1 were used to produce 35 S-Methionine-labeled proteins using the TNT T7 Quick Coupled Transcription/Translation System (Promega). Labeled proteins were TCA precipitated and mixed at equal molar ratios for 30 min at 308C then incubated with competing protein for an additional 30 min. The protein complexes were incubated overnight at 48C with the appropriate antibody: a-His monoclonal antibody (Clonetech), H221 and N20 (Santa Cruz), Ab-1 (Oncogene Science) or p53 monoclonal antibody supernatant (pAb421). Protein A sepharose (Sigma) was used to pull-down the protein-antibody complexes. The complexes were washed twice in 5% sucrose, 1% NP40, 0.5 M NaCl, 50 mM Tris (pH 7.4), 5 mM EDTA (SNNTE) and analysed by SDS ± PAGE.
Cell transfections
Mouse embryo ®broblasts (p53/mdm2 null) or U2OS tumor cells with wild-type p53 were transfected with the appropriate plasmids using Fugene reagent (Boeringer ± Mannheim) per the manufacturers instructions and cells were harvested and analysed 48 h later.
Immunofluorescence
Cells were plated on glass coverslips. At 24 h or after transfection, cells were washed in phosphate-buered saline (PBS) and ®xed in 95% ethanol/5% acetic acid for 5 min at 7208C. Cells were washed three times with PBS, blocked for 30 min at room temperature in 2% horse serum/PBS, and then incubated for 1 h at room temperature in SMP14 (1 : 1000) (Santa Cruz Biotechnology), a-HDM2 polyclonal antibody 93-12 (Montes de Oca Luna et al., 1995) (1 : 1000), or Bp53-12 (1 : 1000) (Santa Cruz Biotechnology) diluted in 2% horse serum/PBS. Cells were washed three times in PBS and then incubated for 1 h at room temperature in Texas Red-conjugated secondary antibody (Vector Laboratories) diluted 1 : 400 in 2% horse serum/PBS. Cells were washed in PBS and mounted onto slides. Photographs were taken with a Zeiss digital microscope with a 406lens.
Western blot analysis
Cell lysates were separated by 10% SDS ± PAGE and transferred to PDVF membranes and incubated with a-HDM2 (1 : 500) overnight at 48C. Signal was detected using ECL kit.
Cell fractionation
Nuclear or cytoplasmic lysates were immunoprecitated with Ab-1 (Oncogene Science) and H221 (Santa Cruz Biotechnology) antibodies, washed twice in SNNTE buer, and proteins separated by SDS ± PAGE. After transfer to membranes, the proteins were detected with N20 (Santa Cruz Biotechnology) antibody.
p53 transcriptional activity U2OS cells were transfected with CMV-bgal (0.4 mg) and p21 promoter-luciferase (El-Deiry et al., 1993) or mdm2-promoter-luciferase (0.5 mg) and CMV-HDM2 (0.5 mg) or CMVHis-ALT (0.5 mg). Cells were harvested at 48 h after transfection and used to determine b-galactosidase and luciferase activities.
